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In science, the important thing is to modify and 
change one’s ideas as science advances.
Herbert Spencer (1820–1903)
Encyclopedia 
of DNA
The completion of the Human Genome
Project in April 2003 was a landmark
accomplishment, but much remains to be
learned before scientists fully understand the
true functionality of the DNA sequences in
our genetic matter. To that end, the
National Human Genome Research Insti-
tute (NHGRI) has initiated a variety of
research projects to better understand the se-
quence. One of the most intriguing and
potentially far-reaching of these efforts is
the Encyclopedia of DNA Elements, or
ENCODE, project, which aspires to create
a complete catalog of all the functional ele-
ments of the human genome.
“The ultimate goal of the ENCODE
project is to create a reference work that will
help researchers fully utilize the human
sequence to gain a deeper understanding of
human biology, as well as to develop new
strategies for preventing and treating dis-
ease,” says Elise A. Feingold, one of the
NHGRI program directors in charge of the
ENCODE project.
The goal of the Human Genome Project
was simply to sequence the human genome;
no distinctions were made between protein
coding and noncoding regions. The
ENCODE project is intended to pick up
where the Human Genome Project left off,
by providing answers about the roles that are
played by the different genetic elements in
the sequence. In addition to studying the
human genome, the ENCODE project is
also looking at genomic sequences from a
variety of animals to provide multispecies
comparisons. This will help to identify con-
served sequences, which are thought to be
strong indicators of functionally important
regions in the human genome.
NHGRI launched ENCODE last year
with the first round of a total $36 million in
grants that will be awarded over a three-year
period. The first round of awards went to 14
recipients in the United States and abroad.
In addition to the grantees, several other aca-
demic and scientific groups are providing
specific technical expertise, such as database
coordination, to assist the project. 
According to Feingold, the grantees and
other contributors are working as a consor-
tium to analyze about 1% of the genome.
Their goal is to determine the most effective
set of methodologies, which will then be
applied to the remaining 99%.
One of the grantees is Anindya Dutta, a
professor of biochemistry and molecular
genetics at the University of Virginia. He
and his colleagues are studying ways to map
replication elements on human chromo-
somes. The completion of the Human
Genome Project created what Dutta consid-
ers an obvious opportunity to embark on
such a replication study. 
“There are very few origins of replication
mapped in human cells—five to ten if you’re
generous, but I would say three or four,”
Dutta says, referring to genetic elements that
are necessary to initiate DNA synthesis. “It
was pretty clear when the sequence of the
human genome came out that this is a great
tool for us to find hundreds of origins and
how they are controlled by chromatin struc-
ture, gene density, promoter activity, and, of
course, sequence.”
Following the model established by the
Human Genome Project, NHGRI is calling
for the data generated by the ENCODE
project to be stored in databases and made
freely available to the scientific community.
The Center for Biomolecular Science and
Engineering at the University of California,
Santa Cruz—which is one of the institu-
tions involved in providing support work
for the ENCODE project and which also
developed the computer programs that ran
the sequencing of the human genome—is
in charge of maintaining the database for
sequence-related ENCODE data. In June
2004 the center added an ENCODE page
(http://genome.ucsc.edu/encode/) to its
existing genome browser, which gets 5,000
visits a day.
It’s not yet clear what might happen fur-
ther with the data after the initial pilot proj-
ect ends in 2006. Feingold says that when
the first period ends, “we will evaluate what
we have learned and determine the best path
for moving forward.” –Richard Dahl
GENOMICS
Encyclopedia genomica. The goal of the ENCODE project of the National Human Genome
Research Institute is to create a complete catalog of all of the functional elements of the human
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BAC to the Future
In  a step forward into the future of gene
expression research, molecular biologists and
neurobiologists have joined forces to map
the genes that control brain structure and
neural circuits. The project, called the Gene
Expression Nervous System Atlas, or GEN-
SAT, maps mouse genes that are also present
in the human genome as expressed in the
central nervous system. According to project
director Nathaniel Heintz, head of the
Laboratory of Molecular Biology at The
Rockefeller University, New York, GENSAT
means that researchers studying degenerative
conditions such as Parkinson disease can
now have access to gene expression within
the brain without having to do their own
molecular genetics from scratch. Some unex-
pected insights have already come to light,
giving neuroscientists new places to search
for the roots of cognitive impairment.
GENSAT is sponsored by the National
Institute of Neurological Disorders and
Stroke (NINDS) and is based at The
Rockefeller University, although prescreen-
ing of candidate genes is conducted by Tom
Curran, chair of developmental neurobiolo-
gy at St. Jude Children’s Research Hospital
in Memphis, Tennessee. In situ hybridiza-
tion is used to screen thousands of candi-
dates to find genes that are active in the
central nervous system. Of these, an adviso-
ry committee selects 250 genes each year
for in-depth analysis by the Rockefeller
group. Says Heintz, “Having an advisory
committee means this research is done with
consensus from many parts of the neuro-
science community.”
Information gathered through the
project is posted in a public database at
http://www.gensat.org/. Started in 2003,
the GENSAT database contains detailed
information for 300 genes and is updated
regularly. With the goal of analyzing 250
genes yearly, the project is planned to run
for at least several more years, according
to Heintz.
The main tools of GENSAT are bacter-
ial artificial chromosomes (BACs), which
are simple loops of bacterial DNA that
reproduce outside the cell. BACs adeptly
incorporate chunks of introduced DNA
from other species, which are preserved and
duplicated along with the BACs. The
Human Genome Project relied on BACs to
help map the human genome. 
To  measure gene activity and patterns
of gene expression in the brain, the GEN-
SAT team inserts a reporter gene for en-
hanced green fluorescent protein into each
BAC. When genes are active, the enhanced
green fluorescent protein glows bright
green. Each BAC is then inserted into eggs
harvested from mice, and the eggs are
implanted into foster mothers. 
The resulting offspring carry the BAC
throughout their bodies in all of the cells
that express the corresponding gene.
Groups of mice are sacrificed at three time
points—two of which correspond to critical
periods of human central nervous system
development—and their brains and spinal
cords are analyzed. Mapping gene activity
at three different points reveals how the
cells migrate and interact. 
The first samples are taken when the
mouse embryos are 15 days old, which
corresponds to the sixth to seventh month
of human gestation. “During this period
the cortex forms, and defects that lead to
malformations occur,” explains project
codirector Mary Beth Hatten, head of the
Laboratory of Developmental Neurobiology
at Rockefeller. The second time point, at 7
days after birth, is equivalent to 6–8 months
of age in humans. At this age, interconnec-
tions form in the cerebellum, which controls
movement, and in the hippocampus, which
controls short-term memory. The final
observations are made on adult mouse
brains at age 7 months, which are similar to
those of 30-year-old humans. 
Findings published in the 30 October
2003 issue of Nature reveal some of the sur-
prising connections the GENSAT project is
uncovering. For example, people with
DiGeorge syndrome, a congenital condition
marked by heart defects and learning disor-
ders, lack a gene called Gscl. Heintz, Hatten,
and other GENSAT researchers discovered
that  Gscl is produced by neurons in the
interpeduncular nucleus, the brain region
that also regulates rapid-eye-movement
sleep. Another finding reported in this paper
relates to the striatum, which degenerates in
patients with Parkinson disease. In end-stage
Parkinson disease, up to 95% of so-called
spiny neurons are lost. Until recently, the
striatum had been the only place where
spiny neurons were found, says Hatten. Yet,
the BAC method identified vectors that can
be used to separately analyze spiny neurons
that project to the substantia nigra and the
globus pallidus. 
The GENSAT methods can also moni-
tor the effects of environmental toxicants,
such as lead, on brain development. “You
can expose the BAC mice to any environ-
mental condition you want, to see how the
migration and maturation of neurons
changes,” says Hatten. 
“The tools and mouse lines provided by
this project allow the neuroscience commu-
nity to perform detailed studies of each
gene,” says Laura Mamounas, the GEN-
SAT project officer at the NINDS. “GEN-
SAT also may serve as a model for future
gene expression projects.” 
Indeed, BAC mice can be used to screen
gene activity in other organs. The BAC mice
are made available to other researchers who
are interested in performing systematic stud-
ies of gene expression. Scientists in other
specialties are “just starting to bootstrap our
efforts to get their particular information,”
says Heintz. –Carol Potera
SYSTEMS BIOLOGY
Mr. Greengenes. The GENSAT project uses en-
hanced green fluorescent protein to map mouse
genes that are also present in humans and expressed
in the central nervous system.The Path to Species
Comparison
Systems biology relies on integrating genetic,
proteomics, and metabolic data, and on
understanding interdependent cellular and
intercellular events that are constantly in flux.
To  accomplish this feat, researchers have
relied on DNA and protein sequence data-
bases and high-throughput expression analy-
sis techniques such as microarrays to produce
ever-growing libraries of expression data.
DNA and protein sequences can be quickly
compared using software tools
such as BLAST (Basic Local
Alignment Search Tool), a pro-
gram that identifies similar
genes in different organisms.
Now scientists are applying this
computational approach to pro-
tein interaction networks, which
are the means by which proteins
communicate.
“As we move from a focus
on sequences to one on net-
works, we need a tool similar to
BLAST,” says Trey Ideker, an
assistant professor of bioengi-
neering at the University of
California, San Diego. The soft-
ware program PathBLAST was
developed to fill this need by a
group consisting of researchers
from Ideker’s lab and the lab of
Brent Stockwell, now an assis-
tant professor of biological sci-
ences at Columbia University.
At  the time, both Ideker and
Stockwell were fellows at the Whitehead
Institute for Biomedical Research in Cam-
bridge, Massachusetts, and worked on the
program development with Richard Karp, a
professor of bioengineering and mathematics
at the University of California, Berkeley,
known for his work in combinatorial algo-
rithms and bioinformatics.
The PathBLAST program rapidly com-
pares protein interaction networks across
two different organisms using fast-execut-
ing algorithms. The program searches for
high-scoring alignments involving one path
from each network. The proteins of the first
path are paired with putative homologs—
or proteins presumed to have a common
origin and function—from the other
species and occurring in the same order in
the second path. PathBLAST is built as a
plug-in to Cytoscape, a widely used soft-
ware platform. Scientists use Cytoscape to
visualize molecular interaction networks
and integrate these interactions with gene
expression profiles and other data.
“The important stuff in biology is
revealed by comparing things,” says Ideker.
“By comparing protein interaction net-
works of two different species or even with-
in species, we can identify pathways and
complexes that have been conserved over
evolution.” These evolutionarily conserved
pathways allow interpretation of the net-
work of a poorly understood organism
based on its similarity to that of a well-
known species. This comparison could pro-
vide a model of signaling and regulatory
pathways that are related to a response to an
environmental toxicant. It could also help
target drugs to pathways that are present in
a pathogenic organism but absent from its
human host. Such a model could further-
more help identify drugs that would repair
damaged pathways or even cause new ones
to be formed.
The PathBLAST development group
published a paper in the 30 September
2003 issue of Proceedings of the National
Academy of Sciences in which they identified
the conserved pathways within the yeast
Saccharomyces cerevisiae and the bacterium
Helicobacter pylori. For example, the authors
found that one pathway that was critical in
catalyzing DNA replication and another in
protein degradation were conserved in both
organisms as a single network. Within sec-
onds, the program had determined that
the bacterium contained 1,465 interac-
tions among 732 proteins, and the yeast
contained 14,489 interactions among
4,688 proteins. 
This report proved that the method
works for matching conserved networks
from among all the networks in two species,
according to software engineer Brian Kelley,
a member of Stockwell’s lab. Kelley says,
“The next step is to prove the software in a
novel application where you start with a
given disease network and see if it is con-
served in other species. Once you prove this
utility, then the use of PathBLAST will sky-
rocket.” Kelley adds that research into the
mTOR cell growth–triggering protein
pathway may prove to be that application.
This pathway is composed of a complex of
proteins that respond to nutrient cues;
understanding it will clarify the role that
nutrients and metabolism play
in disease.
Other researchers have
taken a complementary ap-
proach by comparing what’s
known about a disease to a
known network. At Beyond
Genomics in Waltham, Massa-
chusetts, researchers measure
quantitative differences be-
tween transcripts, proteins,
and metabolites across a given
disease model, determine cor-
relations within the data set,
and then compare the experi-
mentally derived network
with a known biological net-
work or pathway.
“As the protein interaction
databases become more heavily
populated with interactions
among higher eukaryotes,
PathBLAST and related ap-
proaches will start to shine as
they can help elucidate the set
of core biological networks for a given
genome,” says Tom Plasterer, the principal
scientist for bioinformatics at Beyond
Genomics. “These networks—when cou-
pled with a tightly defined experimental
context—will be invaluable in understand-
ing mechanisms of disease, where one
expects compensatory and subtly differing
biological networks to emerge.”
The PathBLAST website is hosted by
the Whitehead Institute and available at
http://www.pathblast.org/; it will soon be
mirrored at the San Diego Supercomputer
Center at the University of California, San
Diego. And as for whether industry will
embrace PathBLAST, Ideker says, “It’s still
early. Speculating too far about these tech-
nologies is like asking industry in 1980,
‘Is genome sequencing going to revolu-
tionize your drug discovery pipeline?’
Even in 2004, the verdict is still out on
that one!” –W. Conard Holton
A 672 VOLUME 112 | NUMBER 12 | August 2004 • Environmental Health Perspectives
D
e
n
n
i
s
 
K
u
n
k
e
l
 
M
i
c
r
o
s
c
o
p
y
Forum
BIOINFORMATICS
Conservation comparison. PathBLAST software allows researchers to identify
protein interaction networks that are conserved across multiple species.
S. cerevisiae H. pyloriActivating Cancer
Drug Discovery
Normal cells that transform into cancer cells
undergo various metabolic changes, includ-
ing shifts in activities of enzymes that medi-
ate macromolecule synthesis and growth-
signaling pathways. Proteomics technology
now provides an elegant way to identi-
fy the enzymes that are active in
processes linked with tumor progres-
sion. As demonstrated by a recent
study conducted at The Burnham
Institute’s Cancer Center in La Jolla,
California, this approach is beginning
to unveil some novel high-efficacy tar-
gets for cancer control and treatment.
In  work published 15 March
2004 in Cancer Research, the Burn-
ham team used a novel proteomics
screen based on probes that bind to
the active site of the enzyme target. By
competing with such probes for the
active site, one can simultaneously
identify protein targets and screen for
their inhibitors. Activity-based pro-
teomics screening is fast emerging as
“the wave of the future,” says coau-
thor Steven J. Kridel, a postdoctoral
fellow at the time of the research and
now an assistant professor of cancer
biology at Wake Forest University of
Winston-Salem, North Carolina—it
enables the generation of hypotheses
that can lead to meaningful clinical
applications. The chemical strategy
for activity-based proteomics was pio-
neered in the laboratories of cell biol-
ogist Ben Cravatt of The Scripps
Research Institute and pathologist
Matthew Bogyo of Stanford Univer-
sity. Kridel and colleague Jeffrey Smith,
associate scientific director for technology
at The Burnham Institute, are among the
first to use the approach to identify a thera-
peutic lead.
The activity-based strategy may mark a
major improvement over the usual pro-
teomics approaches, which are based on the
relative abundance of a particular protein
target. “Measuring the abundance of a pro-
tein only provides a static picture of a poten-
tial target enzyme,” says Kridel. “There are
several levels of regulation between protein
abundance and protein activity. With activ-
ity-based proteomics, you also can tell
whether there is a specific physiologic state
that turns off the enzyme’s activity and
whether an inhibitor of that particular
enzyme exists.” 
Kridel and Smith applied the activity-
based strategy to identify proteins that
exhibit different activities in cancer cells as
compared to normal cells. They screened a
group of enzymes known as serine hydro-
lases by measuring the activity levels of these
enzymes in normal prostate epithelial cells
and in three standard prostate cancer cell
lines. They found that serine hydrolase
expression was generally similar among all
cell lines, with two key exceptions: one of
the hydrolases was active in normal prostate
cells but virtually inactive in all the tumor
cells, while another was expressed in all of
the tumor lines but absent in the normal
cells. The latter enzyme was shown to be
fatty acid synthase (FAS), which had earlier
been strongly linked to tumor progression,
making it an attractive therapeutic target.
Having identified their molecular target
of choice, the investigators then screened
possible inhibitor drugs, hoping to find
unforeseen side benefits in drugs already
approved for human use. “Our goal from
the outset was to find an anticancer drug
that might not have been considered
before,” says Kridel. “We wanted a drug
that inhibits a protein that is only expressed
in cancer cells, not in normal cells, in part
because we believed this would minimize
toxic side effects.” Among the many agents
reviewed was the anti-obesity drug orlistat
(trade name Xenical). Kridel says orlistat
had not previously been shown to inhibit
FAS, and FAS inhibition is not believed to
be relevant to orlistat’s mode of action in
weight loss. 
In  cell culture studies, the Burnham
team found that orlistat inhibited prolifera-
tion and induced apoptosis in at least two
lines of prostate cancer cells. The antiprolif-
erative effects were reversed by the
addition of palmitate, the precursor
for the majority of nonessential fatty
acids, which cancer cells use primarily
for energy and growth. This strongly
implicated FAS inhibition, as FAS is
the only eukaryotic enzyme capable of
synthesizing palmitate. In rodent
experiments, orlistat blocked tumor
growth significantly, and the animals
showed no outward signs of toxicity or
adverse changes in blood chemistry.
By revealing some of the unantici-
pated effects of a drug, activity-based
proteomics could markedly reduce the
cost of drug development. “Orlistat
just happens to be an approved drug
with relatively minor toxicity that
could be utilized quickly once its
effectiveness in human prostate cancer
is validated,” says Massimo Loda, an
associate professor of pathology at
Harvard Medical School and the
Dana Farber Cancer Institute in
Boston, Massachusetts. “The implica-
tions of this study are dual: this activ-
ity-based proteomics approach can
now be applied to the screening of
diverse families of enzymes that sus-
tain tumor survival, and it may reveal
unsuspected activity of known drugs
utilized in diseases other than cancer.”
Such research may eventually pave
the way for construction of a proteomics
profile of susceptibility to cancer progres-
sion. “If a man presents with prostate cancer
and has a biopsy, it is entirely possible that
the proteomics screening approach can be
used to assess whether his tumor has upreg-
ulated FAS,” Smith says. “If it does, you can
then prescribe a specific treatment regimen:
to reduce dietary fat and block FAS activity
using orlistat. This is moving toward per-
sonalized medicine.”
Smith believes a low-fat diet could rein-
force orlistat’s cancer-fighting effects in
humans. “We know that tumor cells have a
unique requirement for fat,” he says. “If you
restrict dietary fat and knock out the tumor’s
ability to synthesize its own fat from carbo-
hydrates, then the antitumor effect should
be even greater.” –M. Nathaniel Mead
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Dual-purpose drug? A novel activity-based proteomics screen
of the weight-loss drug orlistat revealed its surprising potential
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The National Center for Biotechnology Information
(NCBI) of the National Library of Medicine was created
as a means of developing new information technolo-
gies to help advance the field of molecular biology.
Composed of a group of scientists from disciplines
including mathematics, research medicine, and struc-
tural biology, the center’s programs and activities are
centered on both basic and applied research in compu-
tational molecular biology. Since the center’s inception
in 1988, NCBI scientists have developed important novel
algorithms and research approaches in the fields of
computational biology and gene sequencing, among
others. Today, researchers and others can find an
impressive array of “omics” resources and tools collect-
ed into one central resource on the NCBI website at
http://www.ncbi.nlm.nih.gov/. 
General information on the center’s work can be
found within the top center section of the homepage
as well as by clicking the About NCBI link on the left
side of the homepage. A large portion of the NCBI web-
site is devoted to the number of free, publicly accessi-
ble databases and software programs that the center
hosts. Included among the databases on offer are
GenBank, the Online Mendelian Inheritance in Man,
the Cancer Genome Anatomy Project, and numerous
organism-specific genome databases. The site classifies
these databases as literature search databases, molecu-
lar databases, or genomic biology databases to make
finding them easier; GenBank, NIH’s annotated genetic
sequence database, stands under its own heading. The
Molecular Databases page—which is based on Entrez,
the integrated search and retrieval system developed
by the NCBI—has more than 25 additional database
classifications such as nucleotide, protein, and expres-
sion. Entrez can also be quickly accessed through a pull-
down menu at the top of the homepage.
The Genomic Biology section of the site provides a
brief overview of this relatively new area of science.
Visitors to this section will find a wealth of human
genome resources, including a map viewer that can be
used to browse the human genome. By selecting the
Human Genome Resources page, users can access PDF
background documents on the databases available on
the site, two of which provide instructions on how to
use the map viewer to
explore genomes. 
The main portion of
this Genomic Biology area
is divided into sections on
genes and human health
and contains links to
Online Mendelian Inher-
itance in Man, RefSeq,
dbSNP, and Gene Data-
base. Visitors can also
access BLAST for comparing genomic
sequences and gene products, and a central-
ized registry of genomic clones, end
sequences, mapping data, and distributor
information. Other tools are available as well,
and are classified under Maps and Markers,
Transcribed Sequences, Cytogenetics, and
Comparative Genomics.
The right-hand toolbar for the Genomic
Biology section contains resources for 20 spe-
cific organisms. Selecting any one of these
organisms takes the user to a guide outlining
the many different search tools and other
resources offered by the NCBI and other groups. These
resources include gene maps, sequences, and annota-
tion projects.
Educators and others using the site can access an
online guide to GenBank and NCBI resources through the
Education link on the homepage. Also on the Education
page are tutorials for BLAST, Entrez, and other tools
available on the site, as well as access to NCBI newsletters
and map viewer exercises. Also within this section is an
online science primer developed by the NCBI as a way to
familiarize nonspecialists with terms and concepts such as
“genome mapping,” “expressed sequence tags,” and
“phylogenetics.” –Erin E. Dooley